John Thompson, MD
Pulmonary Disease · Lexington, KYNPI 1760496301
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $54,668 of the $76,933 with a category attached, or 71.1%. Boehringer Ingelheim accounts for 82.0% of it on its own, with 48 other manufacturers making up the rest. Reporting peaked in 2023 at $25,583 and has fallen 89.6% since, to $2,649 in 2025. Among pulmonary disease clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 720 payments — averaging $106.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$63K
- Intuitive Surgical$3K
- GSK$2K
- AstraZeneca$1K
- Grifols USA, LLC$723
- Mylan Specialty L.p.$701
- plus $6K from 43 others
Across 1 payment — averaging $2300.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$2K
What the payments were for
- Consulting fees$3,2004%
- Speaking & faculty fees$54,66871%
- Travel & lodging$2,9074%
- Food & beverage$12,54816%
- Education$3,2214%
- Gifts$3901%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$76,933 in reported general payments places this provider in the 90th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 40 | $513,418 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 325 | $302,452 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $219,041 |
| Dupixent PenDupilumab | 49 | $190,267 |
| NucalaMepolizumab | 24 | $174,231 |
| Pirfenidone | 32 | $121,511 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 94 | $72,908 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 73 | $72,897 |
| Breo ElliptaFluticasone/Vilanterol | 93 | $50,007 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 61 | $37,772 |
| Spiriva RespimatTiotropium Bromide | 23 | $23,264 |
| SymbicortBudesonide/Formoterol Fumarate | 42 | $17,940 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 22 | $17,531 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 336 | $9,211 |
| Atrovent HfaIpratropium Bromide | 15 | $7,053 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $63,078 | $627,120179 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,565 | $570,029519 claims |
| Grifols USA, LLCProlastin C | $723 | $219,04113 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,300 | $90,838115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Lexington
- Dennis DohertyLexington$103K
- Ashish MaskeyLexington$94K
- Girish NairLexington$86K
- Anthony GerberLexington$20K
- Eliseo Colon-CarrerasLexington$17K
- Christopher MeenachLexington$15K
- Theresa CaseLexington$14K
- John McConnellLouisville$864K
- Erica GregonisRichmond$390K
- Firas KouraGeorgetown$350K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.